Integral DiagnosticsASX:IDX -0.50%73 PB Ratio is 1.10 as of Jun. 26, 2026, which is 59% below its 10-year median of 2.71. GuruFocus rates ASX:IDX with a GF Score™ of 73/100 and a GF Value™ of A$2.78 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 196 Medical Diagnostics & Research companies, Integral Diagnostics ranks better than 73.98% on this metric.
Integral Diagnostics Ltd stock PB Ratio (=1.09) is close to 10-year low of 1.06.
The historical rank and industry rank for Integral Diagnostics's PB Ratio or its related term are showing as below:
ASX:IDX'
s PB Ratio Range Over the Past 10 Years
Min: 1.06 Med: 2.71 Max: 5.35
Current: 1.1
During the past 10 years, Integral Diagnostics's highest PB Ratio was 5.35. The lowest was 1.06. And the median was 2.71.
ASX:IDX's PB Ratio is ranked better than 73.98% of 196
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.05
vs ASX:IDX: 1.10
During the past 12 months, Integral Diagnostics's average Book Value Per Share Growth Rate was -2.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 7.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 7.40% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Integral Diagnostics was 26.70% per year. The lowest was 0.70% per year. And the median was 11.60% per year.
Back to Basics: PB Ratio
Integral Diagnostics (ASX:IDX) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Integral Diagnostics PB Ratio Related Terms
Integral Diagnostics PB Ratio Historical Data
* Premium members only.
The historical data trend for Integral Diagnostics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Integral Diagnostics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integral Diagnostics PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Integral Diagnostics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Integral Diagnostics (ASX:IDX) has a PB Ratio of 1.10 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Integral Diagnostics and its competitors. This is 59% below median its historical median of 2.71. Over the past decade, Integral Diagnostics' PB Ratio has ranged from 1.06 to 5.35. According to the industry distribution chart, Integral Diagnostics ranks #51 out of 196 companies in the Medical Diagnostics & Research industry, placing it in the top 26%.
Is Integral Diagnostics' PB Ratio too high?
Integral Diagnostics' current PB Ratio of 1.10 is 59% below median its 10-year median of 2.71. Over the past 10 years, this metric has ranged from a low of 1.06 to a high of 5.35. The Medical Diagnostics & Research industry median PB Ratio is 2.05. Integral Diagnostics' value of 1.10 is 46.3% below this industry median. Based on the distribution chart, Integral Diagnostics ranks #51 out of 196 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Integral Diagnostics has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integral Diagnostics ranks #51 out of 196 companies for PB Ratio. This puts Integral Diagnostics in the upper half of its industry. The industry median PB Ratio is 2.05. Integral Diagnostics' value of 1.10 is 46.3% below this benchmark. Historically, Integral Diagnostics' own PB Ratio has ranged from 1.06 to 5.35 over the past decade. While the company's 10-year median is 2.71 vs. the industry median of 2.05, Integral Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.05, based on 196 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integral Diagnostics's current PB Ratio of 1.10 is 46.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Integral Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integral Diagnostics's current PB Ratio is 1.10, which is 59% below median its own 10-year median of 2.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Integral Diagnostics (ASX:IDX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$2.78, compared to a current price of A$2.00 — trading 28.1% below its estimated fair value. The current PB Ratio is 1.10, which is 59% below median its 10-year median of 2.71 and 46.3% below the Medical Diagnostics & Research industry median of 2.05. Integral Diagnostics' overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Integral Diagnostics (ASX:IDX), the current PB Ratio is 1.10 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integral Diagnostics (ASX:IDX) Overvalued in 2026?
Based on GuruFocus' analysis, Integral Diagnostics stock appears to be undervalued.
The current stock price of A$2.00 is trading 28.1% below its estimated GF Value™ of A$2.78.
GuruFocus considers Integral Diagnostics to be Modestly Undervalued.
Key valuation signals for ASX:IDX:
PB Ratio: 1.10 (59% below median its 10-year median of 2.71)
GF Value™: A$2.78 vs. price of A$2.00 (28.1% below fair value)
Industry Position: 46.3% below the Medical Diagnostics & Research median (#51 of 196)
No single metric tells the full story. See the ASX:IDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
73GF Score
Get the complete analysis for ASX:IDX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IDX has been successfully added to your 
